Literature DB >> 25483670

Adolescent vaccines: Need special focus in India.

Ramesh Verma1, Pardeep Khanna1, Suraj Chawla2.   

Abstract

WHO defines adolescence age between 10 to 19 years. In India, there are 243 million adolescents which constitute 21 per cent of the total population. The global burden of disease in adolescents (2011) reports that the total number of disability adjusted life years (DALYs) worldwide among adolescents were 230 million which constitutes 15.5% of total DALYs. The immunization is one of the most important, most beneficial and cost-effective disease prevention measures that can be provided for adolescents. The adolescent vaccination protects most of the world's adolescents from a number of infectious diseases that previously claimed millions of lives each year. In India, thousands of adolescents die and thousands are hospitalized every year due to communicable diseases that could have been prevented by vaccination. Main aims of adolescent vaccinations are: to boost immunity status that is waning after completion of primary immunization or absence of "natural" boosting due exposure to the particular disease. The recommendations for the immunization of adolescents are to improve vaccination coverage among them. The adolescent vaccinations also help in accelerate disease control or elimination effort. Improvement in adolescent immunization coverage in India, will require strengthening of health care delivery system and also require significant improvements in the health care functionaries ability and willingness to provide and deliver vaccines to adolescents.

Entities:  

Keywords:  adolescence; control; disability adjusted life years; elimination; vaccination

Mesh:

Substances:

Year:  2014        PMID: 25483670      PMCID: PMC5054787          DOI: 10.4161/hv.29757

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  15 in total

Review 1.  The changing epidemiology of diphtheria in the vaccine era.

Authors:  A Galazka
Journal:  J Infect Dis       Date:  2000-02       Impact factor: 5.226

2.  Pertussis in developed countries.

Authors:  John B Robbins; Rachel Schneerson; Birger Trollfors
Journal:  Lancet       Date:  2002-08-31       Impact factor: 79.321

3.  Diphtheria, tetanus, pertussis: antibody detection in New Zealand.

Authors:  R C Lau
Journal:  N Z Med J       Date:  1987-08-12

4.  Return of epidemic pertussis in the United States.

Authors:  J W Bass; R R Wittler
Journal:  Pediatr Infect Dis J       Date:  1994-05       Impact factor: 2.129

Review 5.  Global burden of disease in young people aged 10-24 years: a systematic analysis.

Authors:  Fiona M Gore; Paul J N Bloem; George C Patton; Jane Ferguson; Véronique Joseph; Carolyn Coffey; Susan M Sawyer; Colin D Mathers
Journal:  Lancet       Date:  2011-06-07       Impact factor: 79.321

Review 6.  Recommendations are needed for adolescent and adult pertussis immunisation: rationale and strategies for consideration.

Authors:  M Campins-Martí; H K Cheng; K Forsyth; N Guiso; S Halperin; L M Huang; J Mertsola; G Oselka; J Ward; C H Wirsing von König; F Zepp
Journal:  Vaccine       Date:  2001-12-12       Impact factor: 3.641

7.  Population-based incidence of pertussis among adolescents and adults, Minnesota, 1995-1996.

Authors:  P Strebel; J Nordin; K Edwards; J Hunt; J Besser; S Burns; G Amundson; A Baughman; W Wattigney
Journal:  J Infect Dis       Date:  2001-03-30       Impact factor: 5.226

8.  Immunity to diphtheria and tetanus in Australia: a national serosurvey.

Authors:  Heather F Gidding; Josephine L Backhouse; Margaret A Burgess; Gwendolyn L Gilbert
Journal:  Med J Aust       Date:  2005-09-19       Impact factor: 7.738

9.  Immunity against diphtheria and tetanus in German blood donors.

Authors:  Arne Aue; Holger Hennig; Sabine Krüger; Barbara Closius; Holger Kirchner; Michael Seyfarth
Journal:  Med Microbiol Immunol       Date:  2002-11-30       Impact factor: 3.402

10.  Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model.

Authors:  Rakesh Aggarwal; Uday C Ghoshal; Subhash R Naik
Journal:  J Hepatol       Date:  2003-02       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.